NVS

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: PFE MRK JNJ ABBV BMY LLY GILD AMGN REGN VRTX

| Held by: DFIV DFIC DFAI DIHP DFAX AVDE PPH FVD KAT PID

Index	-	P/E	17.98	EPS (ttm)	6.91	Insider Own	0.00%	Shs Outstand	1.94B	Perf Week	-4.32%
Market Cap	235.53B	Forward P/E	13.40	EPS next Y	9.26	Insider Trans	-	Shs Float	1.90B	Perf Month	2.41%
Enterprise Value	261.23B	PEG	2.21	EPS next Q	2.25	Inst Own	7.11%	Short Float	0.23%	Perf Quarter	2.77%
Income	13.74B	P/S	4.40	EPS this Y	13.73%	Inst Trans	-1.40%	Short Ratio	2.88	Perf Half Y	13.76%
Sales	53.55B	P/B	5.72	EPS next Y	4.27%	ROA	13.61%	Short Interest	4.38M	Perf YTD	27.55%
Book/sh	21.69	P/C	33.65	EPS next 5Y	8.14%	ROE	32.82%	52W High	130.46 -4.86%	Perf Year	6.09%
Cash/sh	3.69	P/FCF	12.13	EPS past 3/5Y	-17.97% 13.96%	ROIC	20.80%	52W Low	96.06 29.21%	Perf 3Y	62.06%
Dividend Est.	4.13 (3.32%)	EV/EBITDA	11.29	Sales past 3/5Y	-0.87% 1.13%	Gross Margin	75.38%	Volatility	0.87% 0.93%	Perf 5Y	51.32%
Dividend TTM	3.87 (3.12%)	EV/Sales	4.88	EPS Y/Y TTM	-12.67%	Oper. Margin	32.13%	ATR (14)	1.79	Perf 10Y	53.56%
Dividend Ex-Date	Mar 12, 2025	Quick Ratio	0.62	Sales Y/Y TTM	12.38%	Profit Margin	25.65%	RSI (14)	47.60	Recom	3.00
Dividend Gr. 3/5Y	14.94% 10.29%	Current Ratio	0.82	EPS Q/Q	32.25%	SMA20	-2.03%	Beta	0.63	Target Price	125.44
Payout	55.42%	Debt/Eq	0.78	Sales Q/Q	14.31%	SMA50	2.05%	Rel Volume	1.22	Prev Close	127.70
Employees	75883	LT Debt/Eq	0.57	Earnings	Jul 17 BMO	SMA200	11.24%	Avg Volume	1.52M	Price	124.12
IPO	Nov 07, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.94% -0.11%	Trades		Volume	1,860,972	Change	-2.80%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-12-25	Downgrade	Goldman	Neutral → Sell	$118
Aug-08-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$123
Feb-13-25	Downgrade	UBS	Buy → Neutral
Feb-12-25	Initiated	Morgan Stanley	Underweight
Feb-04-25	Upgrade	Deutsche Bank	Hold → Buy
Dec-04-24	Downgrade	HSBC Securities	Hold → Reduce
Sep-11-24	Downgrade	BofA Securities	Buy → Neutral	$135 → $130
Sep-05-24	Downgrade	Goldman	Buy → Neutral
Sep-03-24	Downgrade	Jefferies	Buy → Hold
Jul-19-24	Downgrade	Deutsche Bank	Buy → Hold
May-30-24	Initiated	Goldman	Buy	$120
Feb-23-24	Initiated	BMO Capital Markets	Market Perform	$114
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$114
Jan-16-24	Resumed	UBS	Buy
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Sep-25-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-26-23	Upgrade	Deutsche Bank	Hold → Buy
Mar-27-23	Upgrade	Deutsche Bank	Sell → Hold
Jan-26-23	Downgrade	Citigroup	Buy → Neutral

Show Previous Ratings

Sep-12-25 08:14PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
12:11PM	Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. (Barrons.com)
10:38AM	OLMA Stock Soars 47% in September So Far on Second PFE Deal (Zacks)
09:39AM	Molson Coors downgraded, GM upgraded: Wall Street's top analyst calls (The Fly)
Sep-11-25 04:25AM	Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer (Zacks)
11:08AM	Loading…
Sep-10-25 11:08AM	5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds (Zacks)
11:06AM	NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline (Zacks)
Sep-09-25 05:34PM	Novartis to Acquire Tourmaline Bio in $1.4 Billion Deal (GuruFocus.com)
04:06PM	Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense' (Investor's Business Daily)
11:49AM	Palantir Stock Is Rising. Customers Continue to Use the AI Software, Analysts Say. (Barrons.com)
10:36AM	Novartis & Tourmaline, Anglo American & Teck, CoreWeave AI fund (Yahoo Finance Video)
08:16AM	Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver (MarketBeat)
07:28AM	This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It. (Barrons.com)
05:39AM	Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range (MarketWatch)
Sep-05-25 03:46PM	This Warren Buffett Stock, Two Others, Hit New Highs (Investor's Business Daily)
10:45AM	Loading…
10:45AM	The Zacks Analyst Blog Highlights Apple, Novartis, Charles Schwab, Community Bancorp and Optex Systems (Zacks)
Sep-04-25 04:29PM	Top Stock Reports for Apple, Novartis & Charles Schwab (Zacks)
03:00PM	Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity? (Zacks)
Sep-03-25 09:42AM	NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy (Zacks)
07:00AM	Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases (PR Newswire)
Sep-02-25 04:05PM	Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion (Investor's Business Daily)
Aug-31-25 02:08AM	Novartis (NVS) Strengthens Outlook With Ianalumab Trial Success and Leqvio Expansion (Insider Monkey)
Aug-28-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Aug-26-25 09:31AM	Can Label Expansion of Cabometyx Fuel Further Growth for EXEL? (Zacks)
Aug-25-25 02:23PM	RNA Stock Moves More Than 30% in a Week: What's Driving This Rally? (Zacks)
Aug-20-25 10:18AM	INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold? (Zacks)
Aug-19-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:33AM	Will EXEL's Share Repurchase Program Boost Value for Investors? (Zacks)
Aug-18-25 09:00AM	Atropos Health Enters into Strategic Collaboration to Reduce Time to Rare Disease Diagnosis with Artificial Intelligence (AI) Algorithm (Business Wire)
01:15AM	New Novartis ESC data highlights strength of cardiovascular portfolio (GlobeNewswire)
07:23PM	Loading…
Aug-17-25 07:23PM	Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm (Motley Fool)
Aug-15-25 08:15AM	2 Dividend Stocks to Buy and Hold (Motley Fool)
Aug-13-25 08:36AM	Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition? (Zacks)
Aug-12-25 09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
04:28AM	Novartis shares slightly up after Ianalumab meets goals in Phase 3 trial (Investing.com)
02:05AM	Novartiss Ianalumab Meets Goals in Phase 3 Trial to Treat Autoimmune Disease (The Wall Street Journal)
01:15AM	Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure (GlobeNewswire)
Aug-11-25 11:30AM	Barrick Mining, Rheinmetall, Novartis: Global Stocks in Focus (The Wall Street Journal)
07:16AM	Rheinmetall, Ørsted, Novartis: Global Stocks in Focus (The Wall Street Journal)
01:20AM	Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease (PR Newswire)
01:20AM	Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjogren's disease (PR Newswire)
Aug-06-25 04:53PM	Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal (Investor's Business Daily)
12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com)
Aug-01-25 11:49AM	ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up (Zacks)
Jul-31-25 04:30PM	Novartis twice-yearly* Leqvio (inclisiran) receives FDA approval for new indication enabling first-line use (PR Newswire)
04:16PM	What Trump's Big Pharma CEO letters mean for drug pricing power (Yahoo Finance Video)
09:10AM	Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook (Zacks)
Jul-29-25 11:45AM	INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales (Zacks)
Jul-24-25 11:42AM	Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards? (Zacks)
09:40AM	Here's Why Novartis (NVS) is a Strong Value Stock (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Jul-22-25 11:43AM	AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures (Zacks)
06:20AM	Should You Invest in the VanEck Pharmaceutical ETF (PPH)? (Zacks)
Jul-21-25 06:28PM	Kisqali Emerges as Novartis AG (NVS) Blockbuster with Record Q2 Growth (Insider Monkey)
09:41AM	Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025 (Zacks)
08:55AM	Novartis AG (NVS): Jim Cramer Wonders Whether Its CEO Is Leaving (Insider Monkey)
Jul-20-25 10:49AM	Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm. (Motley Fool)
Jul-18-25 06:11PM	Analyst Report: Novartis AG (Morningstar Research)
10:22AM	Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data (Zacks)
03:06AM	Novartis AG (NVS) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic Initiatives ... (GuruFocus.com)
Jul-17-25 10:00PM	Analyst Report: Novartis AG (Morningstar Research)
04:12PM	Novartis Sacrifices A Breakout As One Of Its Bread-And-Butter Drugs Misses (Investor's Business Daily)
04:08PM	Novartis CEO: We're in open discussions with the Trump administration (CNBC TV)
01:30PM	Novartis CEO on pharma tariffs, raised outlook, competition (Yahoo Finance Video)
12:22PM	Novartis Raises Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback (CORRECTED) (Benzinga)
12:22PM	Tariffs are an overhang on pharma sector, but we will comeback, says Novartis CEO Vas Narasimhan (CNBC TV)
10:35AM	Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook (The Wall Street Journal)
09:40AM	Novartis Beats on Q2 Earnings and Sales, CFO Retires, Stock Down (Zacks)
09:30AM	Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics (Zacks)
08:53AM	Novartis Makes A Bearish Move As One Of Its Bread-And-Butter Drugs Misses (Investor's Business Daily)
08:15AM	Trump & Coca-Cola, Novartis earnings, Netflix preview: Trending Tickers (Yahoo Finance Video)
01:33AM	Novartis Lifts Profit Outlook After Growth in Sales, Earnings (The Wall Street Journal)
01:05AM	Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company (GlobeNewswire)
01:00AM	Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance (GlobeNewswire)
Jul-16-25 07:00PM	Netflix & TSMC earnings, retail sales, Fed talk: What to Watch (Yahoo Finance Video)
09:42AM	Novartis fails to block MSN from selling generic heart drug Entresto (Investing.com)
Jul-15-25 04:55PM	3 Medical Stocks to Watch as Q2 Earnings Approach: ABT, JNJ, NVS (Zacks)
09:50AM	Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? (Zacks)
Jul-14-25 09:32AM	Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart Failure (Zacks)
09:15AM	Exploring Analyst Estimates for Novartis (NVS) Q2 Earnings, Beyond Revenue and EPS (Zacks)
Jul-12-25 09:36AM	FDA willing to trade faster drug reviews for lower prices, Bloomberg reports (TipRanks)
Jul-11-25 10:10AM	Bayer Wins Hormone-Free Treatment Approval for Women in the UK (Zacks)
Jul-10-25 09:34AM	Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump (Zacks)
Jul-09-25 07:29AM	Trump's Drug Tariffs: Where Does the U.S. Import Pharmaceuticals From? (The Wall Street Journal)
Jul-08-25 09:40AM	Why Novartis (NVS) is a Top Value Stock for the Long-Term (Zacks)
01:15AM	Novartis receives approval for first malaria medicine for newborn babies and young infants (GlobeNewswire)
Jul-07-25 09:50AM	Here's Why Novartis (NVS) is a Strong Momentum Stock (Zacks)
Jul-03-25 10:32AM	Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study (Zacks)
09:16AM	FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug (Zacks)
01:25AM	Novartis provides update on Phase III GCAptAIN study of Cosentyx in giant cell arteritis (GCA) (PR Newswire)
Jul-02-25 09:44AM	Buy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July Start (Zacks)
Jul-01-25 09:33AM	Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock? (Zacks)
09:15AM	Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Jun-26-25 02:04PM	Final Trades: Novartis, Sixth Street, Amazon and the IYF (CNBC TV)
Jun-25-25 04:19PM	Can Biogen Save Even More Kids With This New Drug? (Investor's Business Daily)
09:13AM	Novartis completes acquisition of Regulus Therapeutics (GlobeNewswire)
07:30AM	Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? (Investor's Business Daily)
01:00AM	Novartis announces expiration of Regulus Therapeutics tender offer (GlobeNewswire)
Jun-24-25 05:51PM	Novartis AG (NVS): A Bull Case Theory (Insider Monkey)
04:53PM	Top Analyst Reports for JPMorgan, Novartis & AT&T (Zacks)

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Marshall Fiona	Officer	May 23 '25	Proposed Sale	112.68	15,000	1,690,181		May 23 03:40 PM
Kowalski Robert William	Officer	Apr 30 '25	Proposed Sale	113.28	1,212	137,297		Apr 30 01:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Novartis AG ADR

Upgrade your FINVIZ experience